{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:23:57Z","timestamp":1791926637441,"version":"4.3.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Clinical and histomorphometric outcome was compared between children with OI who had received pamidronate since infancy and age-matched patients who had never received pamidronate. Pamidronate was associated with improved vertebral shape and mass, higher cortical width, increased cancellous bone volume, and suppressed bone turnover.<\/jats:p>\n               <jats:p>Introduction: Observations in small patient series indicate that infants with severe osteogenesis imperfecta (OI) benefit from treatment with cyclical intravenous pamidronate. However, detailed analyses of outcome are lacking for this age group.<\/jats:p>\n               <jats:p>Materials and Methods: Clinical outcome was evaluated in 29 children with OI types I (n = 3), III (n = 14), or IV (n = 12) who started pamidronate therapy before 2 years of age (age at treatment onset: median, 6 months; range, 2 weeks to 23 months) and who had completed 3 years of treatment (total annual pamidronate dose, 9 mg\/kg). They were compared with a historical control group of 29 untreated children with severe OI who were matched for OI type and age at the 3-year treatment time-point. In addition, iliac bone histomorphometry was compared between 24 pamidronate-treated patients and 24 age-matched OI patients who had not received pamidronate.<\/jats:p>\n               <jats:p>Results: Morphometric evaluation of lumbar vertebrae (L1-L4) showed that the shape of vertebral bodies was better preserved in pamidronate-treated patients. This was accompanied by significantly higher lumbar spine areal and volumetric BMD (+110 and +96%, respectively) and a larger vertebral bone volume (+26%) on densitometry. Regarding mobility function, the Pediatric Evaluation of Disability Inventory gross motor score was 50% greater in the pamidronate group (p &amp;lt; 0.001). Iliac bone histomorphometry showed 61% higher cortical width and 89% higher cancellous bone volume in pamidronate-treated patients. Bone formation rate per bone surface in the pamidronate group was only 17% that of untreated patients.<\/jats:p>\n               <jats:p>Conclusions: In conclusion, this study suggests that cyclical pamidronate treatment started in infancy leads to improved bone strength and better gross motor function but also suppresses bone turnover markedly. It is therefore prudent to reserve pamidronate treatment to infant OI patients who present with a moderate to severe phenotype.<\/jats:p>","DOI":"10.1359\/jbmr.050213","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T08:53:54Z","timestamp":1146128034000},"page":"1235-1243","source":"Crossref","is-referenced-by-count":129,"title":["Effects of Intravenous Pamidronate Treatment in Infants With Osteogenesis Imperfecta: Clinical and Histomorphometric Outcome"],"prefix":"10.1093","volume":"20","author":[{"given":"Craig FJ","family":"Munns","sequence":"first","affiliation":[{"name":"The Children's Hospital at Westmead; Westmead, New South Wales, Australia"},{"name":"Genetics Unit, Shriners Hospital for Children and McGill University, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Rauch","sequence":"additional","affiliation":[{"name":"Genetics Unit, Shriners Hospital for Children and McGill University, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Travers","sequence":"additional","affiliation":[{"name":"Genetics Unit, Shriners Hospital for Children and McGill University, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis H","family":"Glorieux","sequence":"additional","affiliation":[{"name":"Genetics Unit, Shriners Hospital for Children and McGill University, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024013019244787900_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"key":"2024013019244787900_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S8756-3282(99)00257-4","article-title":"Normative data for iliac bone histomorphometry in growing children","volume":"26","author":"Glorieux","year":"2000","journal-title":"Bone"},{"key":"2024013019244787900_bib3","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"key":"2024013019244787900_bib4","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/adc.86.5.356","article-title":"Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta","volume":"86","author":"Astrom","year":"2002","journal-title":"Arch Dis Child"},{"key":"2024013019244787900_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1515\/JPEM.2002.15.2.163","article-title":"Pamidronate treatment of osteogenesis imperfecta-lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response","volume":"15","author":"Zacharin","year":"2002","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2024013019244787900_bib6","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","article-title":"The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta","volume":"110","author":"Rauch","year":"2002","journal-title":"J Clin Invest"},{"key":"2024013019244787900_bib7","first-page":"1846","article-title":"Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age","volume":"85","author":"Plotkin","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019244787900_bib8","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/adc.86.5.356","article-title":"Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta","volume":"86","author":"Astrom","year":"2002","journal-title":"Arch Dis Child"},{"key":"2024013019244787900_bib9","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1023\/A:1022099425316","article-title":"Pamidronate treatment of severe osteogenesis imperfecta in a newborn infant","volume":"25","author":"Chien","year":"2002","journal-title":"J Inherit Metab Dis"},{"key":"2024013019244787900_bib10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1542\/peds.111.3.573","article-title":"Intravenous bisphosphonate therapy in children with osteogenesis imperfecta","volume":"111","author":"Falk","year":"2003","journal-title":"Pediatrics"},{"key":"2024013019244787900_bib11","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.bone.2004.07.003","article-title":"Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta","volume":"35","author":"DiMeglio","year":"2004","journal-title":"Bone"},{"key":"2024013019244787900_bib12","first-page":"77","article-title":"Modern approach to children with osteogenesis imperfecta","volume":"12","author":"Zeitlin","year":"2003","journal-title":"J Pediatr Orthop B"},{"key":"2024013019244787900_bib13","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/ptj\/70.10.602","article-title":"Concurrent and construct validity of the Pediatric Evaluation of Disability Inventory","volume":"70","author":"Feldman","year":"1990","journal-title":"Phys Ther"},{"key":"2024013019244787900_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00003086-198109000-00015","article-title":"Nonoperative treatment of osteogenesis imperfecta: Orthotic and mobility management","volume":"159","author":"Bleck","year":"1981","journal-title":"Clin Orthop"},{"key":"2024013019244787900_bib15","volume-title":"Radiographic Atlas of Skeletal Development of the Hand and Wrist","author":"Greulich","year":"1959","edition":"2nd ed."},{"key":"2024013019244787900_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00004424-196801000-00005","article-title":"Age changes in five parameters of metacarpal growth","volume":"3","author":"Spencer","year":"1968","journal-title":"Invest Radiol"},{"key":"2024013019244787900_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/jbmr.5650060106","article-title":"A comparison of morphometric definitions of vertebral fracture","volume":"6","author":"Smith-Bindman","year":"1991","journal-title":"J Bone Miner Res"},{"key":"2024013019244787900_bib18","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1651-2227.1992.tb12152.x","article-title":"Lumbar bone mineral content measured by dual energy X-ray absorptiometry in newborns and infants","volume":"81","author":"Salle","year":"1992","journal-title":"Acta Paediatr"},{"key":"2024013019244787900_bib19","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1359\/jbmr.2003.18.4.610","article-title":"Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: Effect of intravenous pamidronate therapy","volume":"18","author":"Rauch","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024013019244787900_bib20","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1210\/jc.2002-021371","article-title":"Osteogenesis imperfecta types I, III and IV: Effect of pamidronate therapy on bone and mineral metabolism","volume":"88","author":"Rauch","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019244787900_bib21","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee","volume":"2","author":"Parfitt","year":"1987","journal-title":"J Bone Miner Res"},{"key":"2024013019244787900_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-0185(199705)248:1<1::AID-AR1>3.0.CO;2-Z","article-title":"Quantitative analysis of trabecular morphogenesis in the human costochondral junction during the postnatal period in normal subjects","volume":"248","author":"Fazzalari","year":"1997","journal-title":"Anat Rec"},{"key":"2024013019244787900_bib23","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/ar.a.10092","article-title":"Cellular mechanism of inhibition of osteoclastic resorption of bone and calcified cartilage by long-term pamidronate administration in ovariectomized mature rats","volume":"274A","author":"Mayahara","year":"2003","journal-title":"Anat Rec"},{"key":"2024013019244787900_bib24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis","volume":"349","author":"Whyte","year":"2003","journal-title":"N Engl J Med"},{"key":"2024013019244787900_bib25","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S8756-3282(01)00615-9","article-title":"Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis","volume":"29","author":"Halasy-Nagy","year":"2001","journal-title":"Bone"},{"key":"2024013019244787900_bib26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bone.2004.03.008","article-title":"Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta","volume":"35","author":"Munns","year":"2004","journal-title":"Bone"},{"key":"2024013019244787900_bib27","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1359\/jbmr.2000.15.4.613","article-title":"Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib","volume":"15","author":"Mashiba","year":"2000","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2FJBMR.050213","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/20\/7\/1235\/56479222\/5650200719.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/20\/7\/1235\/56479222\/5650200719.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:09:01Z","timestamp":1710342541000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/20\/7\/1235-1243\/7593263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,1]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2005,7,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.050213","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,7,1]]},"published":{"date-parts":[[2005,7,1]]}}}